Table 5.

Factors proposed to have a potential effect on anxiety among patients.

Factors affecting anxiety	Anxiety score			Test of significance (p-value)
	Mean±Standard deviation	Median	Minimum-maximum
Phenotype of MS				Kruskal Wallis
RRMS (n = 96)	12.5 ± 10.2	10.0	0–40	X2=0.762 P = 0.683
SPMS (n = 16)	13.9 ± 7.9	11.0	2–26
PPMS (n = 3)	14.7 ± 17.5	10.0	0–34
DMT type				Mann Whitney z = 0.127 P = 0.899
Lymphopenia (n = 25)	12.8 ± 10.0	10.0	0–30
Non-lymphopenia (n = 54)	12.9 ± 10.1	11.0	0–40
MS patients at high risk of COVID⁎⁎				Kruskal Wallis X2=11.515 P = 0.009*
Yes (n = 45)	14.0 ± 11.0	12.0	0–34
It depends on certain factors (n = 38)	10.5 ± 8.7	9.0	0–30
Don't know (n = 27)	15.3 ± 9.5	16.0	0–40
Exposure to a probable case of COVID-19				Mann Whitney z = 0.642 P = 0.521
No (n = 102)	12.5 ± 9.9	10.0	0–40
Yes (n = 13)	14.6 ± 11.1	12.0	0–30
	Correlation coefficient (r)			p-value
Patients’ age	−0.0.252			0.007*
MS disease duration	−0.123			0.196
EDSS	0.234			0.013*

r: spearman coefficient,.

^⁎Significant at (P ≤ 0.05),.

^⁎⁎the participants who answered no (n = 3) were normal as regards anxiety.